AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03323463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
Study NCT03323463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
Study NCT03323463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: Proton beam using pencil beam delivery either with the Varian or IBA delivery systems will be allowed for Cohort B. Proton beam therapy will be given at the New York Proton Center in New York City, where MSKCC has a well-established business associate agreement and cooperative research agreement with, respectively. If treatment at NYPC is not feasible, patients may be referred to ProCure in Somerset, NJ.
Study NCT02778685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT02778685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02778685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT02778685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02778685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02313675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT02240251 — intervention group
Intervention type: OTHER
Intervention: Prospective Chart Review
Description: The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
Study NCT03503955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap-Motion virtual reality games
Description: Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
Study NCT03503955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fine motor skills activities
Description: activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
Study NCT00556608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinovial® (syringe containing sodium hyaluronate solution)
Description: 2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
Study NCT00556608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc® ( syringe containing Hylan G-F 20 solution)
Description: 2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
Study NCT04123093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noxsano Bandage (Healthy Volunteers)
Description: Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
Study NCT04123093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noxsano Bandage (Wound Care)
Description: Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
Study NCT03723330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant sterols
Description: Consumption a healthy eating pattern diet with a plant sterols-enriched food product
Study NCT03723330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet
Description: Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
Study NCT03723330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
Study NCT02855866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Study NCT02855866 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: thyroidectomy
Study NCT03074591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose 50Mg/Ml Inj 15Ml
Description: After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
Study NCT03074591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
Study NCT02313675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Study NCT02855866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy
Study NCT02855866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortisone aerosol
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone acetate
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Study NCT02855866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Study NCT02973347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent enteral feeding
Description: The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
Study NCT02973347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous enteral feeding
Description: The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
Study NCT02313675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00831688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Meniett(C) device by MedTronic
Description: pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
Study NCT00831688 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
Study NCT02260024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high caloric meal
Study NCT02260024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole IR tablets
Study NCT02260024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C
Study NCT02260024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2
Study NCT02260024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2A
Study NCT02260024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR C2B
Study NCT02368041 — intervention group
Intervention type: DEVICE
Intervention: InSpectraTM StO2 monitor
Description: InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
Study NCT00003459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
Study NCT01785446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effect of dexmedetomidine on cisatracurium and sufentanil consumption
Description: In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
Study NCT04353375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
Study NCT03660202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Firesorb
Description: Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
Study NCT01663116 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: 1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15
Study NCT04176198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusivertib
Description: Oral PIM Inhibitor
Study NCT01663116 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15
Study NCT04167059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered participation strategies to increase physical activity
Description: Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
Study NCT04425161 — intervention group
Intervention type: OTHER
Intervention: Fluid challenge (0.9 % NaCl)
Description: 500 ml Fluid challenge of (0.9 % NaCl) will be given
Study NCT02364973 — intervention group
Intervention type: OTHER
Intervention: PET-MRI
Description: The study patients undergo positron emission tomography (PET) after informed consent is obtained
Study NCT01295502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01295502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01295502 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01295502 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT01295502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00859053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, single dose, one day
Study NCT04176198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral JAK inhibitor
Study NCT04176198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Oral JAK inhibitor
Study NCT03217422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAY736
Description: VAY736
Study NCT03217422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control with conversion to active VAY736
Study NCT01114178 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: self completed questionnaire supervised by a technician
Study NCT03708224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given intravenously (IV)
Study NCT03708224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study NCT03708224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study NCT03618771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
Study NCT02710981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
Study NCT02710981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
Study NCT02710981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil vaginal gel
Description: In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
Study NCT00694837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
Study NCT00328887 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD40 Gene Transfer
Description: gene transfer, intratumoral administration
Study NCT04240041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcerebellar diamater
Description: Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
Study NCT04240041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Placental thickness
Description: Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
Study NCT02745704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa
Description: peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
Study NCT03516773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB612 (EBP05)
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally
Study NCT03516773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NATPARA/NATPAR
Description: A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
Study NCT02813096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folfox4 chemotherapy regimen
Description: Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Study NCT02287818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily from Day 1 to Week 12
Study NCT02287818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-201
Description: AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
Study NCT02813096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops.
Study NCT05337111 — intervention group
Intervention type: OTHER
Intervention: Cardiorespiratory fitness test
Description: Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
Study NCT05337111 — intervention group
Intervention type: OTHER
Intervention: Resting measure of fat oxidation
Description: Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
Study NCT00869895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7050
Description: Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
Study NCT04161989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acids
Description: . The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
Study NCT04161989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vaginal progesterone
Description: Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
Study NCT02706470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.